New Recommendations for BRCA Testing Should You Be Screened Skip to main content Close Select your preferred language English عربى 简体中文 繁體中文 فارسي עִברִית 日本語 한국어 Русский Español Tagalog Menu Close Call 1-800-CEDARS-1 toggle search form Close Los Angeles, 12 September 2019 06:00 AM America/Los_Angeles New Recommendations for BRCA Testing Should You Be Screened More women are being encouraged to undergo DNA screening, based on newly announced recommendations. Illustration by Getty. Eager to learn about her family tree, Dorothy Pomerantz sent a saliva sample to an online testing company last summer. To her "utter shock," the results revealed that she has a gene mutation called BRCA1, which greatly increases her risk for breast and ovarian cancer. Despite the challenges of dealing with the genetic information and its aftermath, she said she is grateful that she learned about the mutation before cancer struck. "I was able to be proactive and take steps that will help me stay healthy for many years to come," said the journalist, 48, who subsequently underwent preventive surgeries to remove her breasts and ovaries. More women than ever are being encouraged to undergo screening for BRCA gene mutations, based on newly announced U.S. Preventive Services Task Force recommendations. The task force, an independent, volunteer body of experts in primary and preventive medicine, recommended that two groups of women -- women of Ashkenazie Jewish descent and women who have been diagnosed with breast, ovarian or tubal cancer in the past and who have completed treatment -- should undergo a medical risk assessment to see if they should have genetic counseling. If indicated, counseling would be followed by genetic testing. The previous task force recommendations, issued in 2013, called for screening only women who have a family history of breast, ovarian, tubal or peritoneal cancer. But women who are of Ashkenazi Jewish heritage - meaning that their ancestors hailed from Poland, Russia, Hungary and other central or eastern European countries - are at significantly higher risk for breast and ovarian cancers than other women. About 1 in 40 Ashkenazi Jewish women inherits one of the BRCA mutations, which are responsible for about 5% to 10% of breast cancer cases and 15% of ovarian cancer cases. In the general population, BRCA1 and BRCA2 mutations occur in about 1 in 300 to 500 women, according to the task force. Everyone is born with BRCA1 and BRCA2 genes, which typically help fight cancers. But some mutations in BRCA genes prevent them from working, according to the Centers for Disease Control and Prevention. Those who inherit either of the mutations are at higher risk not only for breast and ovarian cancers, but also prostate and pancreatic cancers. Not everyone who inherits a BRCA1 or BRCA2 mutation will get those cancers, though. Critics of the new recommendations say they don't go far enough. They believe that all women should be tested for BRCA1 and BRCA2. Other health professionals take a more nuanced view. "The U.S. healthcare system is not equipped to appropriately handle such a vast screening undertaking," said John E. Lee, MS, LCGC, program manager at the Genetic Counseling Clinic at Cedars-Sinai. "Still, I believe that everyone with newly diagnosed breast or ovarian cancer should get the screening to help guide their surgical and other treatment decisions." He additionally recommends that every member of a family with a history of ovarian cancer, male breast cancer, rare cancers or cancer diagnoses at an early age should undergo genetic testing. Several tests are available to detect harmful BRCA1 and BRCA2 gene mutations. Some look for a specific mutation that has already been identified in another family member. Others check for all of the known harmful mutations in both. Lee recommends that primary care doctors refer patients to a genetic counselor, who can help determine if family history and risk factors call for testing. Counselors can administer the test and properly interpret the results when they're in - they take about three weeks. Genetic tests can be done in a primary-care doctor's office. The physician sends the patient's blood or saliva sample to a commercial laboratory or a research testing facility. DNA from the sample is used to test for mutations. Consumers interested in online testing should make sure that those companies offer telephone counseling and provide clinical-grade testing. Be cautious, Lee said, of companies that don't offer counseling. "Also, make sure that the companies look at the concerning aspects of the patient's family health history to determine if additional testing is recommended," Lee said. The average cost of genetic testing, if you pay out of pocket, is about $250 but can be higher if multiple genes are analyzed. Genetic counseling often is covered by insurance, especially if there is a family history of BRCA-related cancers. Genetic testing may sound like a worrisome endurance test, but many people who undergo it believe it's worth it. Pomerantz certainly does. "On every step of this journey, I was aware of one glaring fact: All of this would have been infinitely more difficult if I had to do it while also fighting cancer," she said. "I believe that knowledge is power, and I'm glad I can read the story my genes have to tell." To make an appointment with a Cedars-Sinai genetic counselor, call the scheduling department at 310-423-3696. Read more on the Cedars-Sinai Blog: "What's My Breast Cancer Risk?" Related Stories RSS feed - Related Stories (opens in new window) View all headlines - Related Stories Cancer Patient Sails Again September 19, 2022 06:00 AM America/Los_Angeles Jeannea Jordan, who turns 80 in October, is a local sailing pioneer who began racing and cruising her 30-foot sailboat 25 years ago when few women were part of the sport. When a tumor on her spine ran her aground last year and her oncologist at … Read more Study Active Surveillance an Effective Option for Thyroid Cancer September 15, 2022 08:01 AM America/Los_Angeles A novel clinical trial from Cedars-Sinai Cancer shows that active surveillance is an effective treatment for many low-risk thyroid cancer patients. The study, published in JAMA Oncology, also showed for the first time that patients who opted for … Read more Study Patients Prefer Stool Test to Colonoscopy September 12, 2022 10:00 AM America/Los_Angeles Three-quarters of people prefer to do a fecal immunochemical test (FIT) rather than a colonoscopy for their regular colorectal cancer screening, according to a new Cedars-Sinai study.Unlike colonoscopies, FIT doesn’t require lengthy preparation, … Read more Show previous items Show next items Contact the Media Team Email: [email protected] Contact Share this release New Recommendations for BRCA Testing Should You Be Screened Share on: Twitter Share on: Facebook Share on: LinkedIn Search Our Newsroom Social media Visit our Facebook page (opens in new window) Follow us on Twitter (opens in new window) Visit our Youtube profile (opens in new window) (opens in new window) Latest news 07 Oct 2022 - HealthDay: Black Women Less Likely to Get Laparoscopic Fibroid Surgeries 07 Oct 2022 - Faculty Publications: Sept. 29-Oct. 6 07 Oct 2022 - Fine-Tuning Organ-Chip Technology 06 Oct 2022 - KCRW: Want New Omicron Booster? Wait at Least 2 Months After Last Shot 05 Oct 2022 - Cedars-Sinai Schedules Free Flu Vaccine Clinics 04 Oct 2022 - Cedars-Sinai Showcases Hispanic and Latinx Art Newsroom Home